Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless ...

The antithrombin assay will support dosing Qfitlia, the sixth Alnylam-discovered RNAi medicine to receive FDA approval.

Pharmaceuticals announced moderated poster presentations of new data from the HELIOS-B Phase 3 clinical trial, which evaluated ...

CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...

In his resignation letter, Marks cited disagreement with HHS Secretary Robert F. Kennedy Jr., who he said pushed ...

The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare ...

Pharmaceuticals highlighted the significance of the FDA approval of Qfitlia, the sixth Alnylam-discovered RNAi therapeutic ...

Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...

Cardiology drug and device makers will be back in the spotlight this weekend as the annual scientific meeting of the American ...

In the last week, the United States market has stayed flat, but it is up 7.8% over the past year with earnings forecast to grow by 14% annually. In this context of steady growth and positive ...

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Amvuttra operates via RNA interference (RNAi), a groundbreaking technology that inhibits the production of the TTR protein in ...